Incubate’s John Stanford on why MFN’s first casualty is the moonshot — and why cancer, Alzheimer’s, and rare disease bear the cost.
|Videos|November 22, 2022
PharmExec Interviews Alejandra Betancourt at Pharma 2022
Advertisement
In this video, Alejandra Betancourt, Global Director Marketing Operations, Novo Nordisk discusses the hands-on approach to its Content Hub 2.0 and how pragmatic approaches win the day.
Advertisement
Related to this article
Incubate’s John Stanford on why MFN reduces pharma’s appetite for biotech acquisitions — and why that cedes ground to China.
Incubate’s John Stanford on why MFN deals are voluntary in name only — and why the leverage looks a lot like the IRA’s 95% excise tax.
Incubate’s John Stanford on why MFN hits mid-sized pharma harder — fewer products to absorb margin hits and less access to cheap capital.
Fox Rothschild's Marc Wagner on why domestic manufacturing reduces drug shortage risk — and why FDA inspection efficiency is as important as supply chain resilience.
Fox Rothschild's Marc Wagner on how 503A pharmacies and 503B outsourcing facilities fill drug supply gaps — from COVID injectables to GLP-1s.
Fox Rothschild's Marc Wagner on why scaling drug production is so slow — overseas API sourcing, supplier qualification, and FDA site approvals that take years.
Waiting for perfect data before deploying AI is a trap — and why 60-70% accuracy is often good enough to start.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Grants Ultomiris Accelerated Approval in the U.S. for Adults with Primary Immunoglobulin A Nephropathy
2
FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B
3
Roundup: Alcon Acquires Neurotech and Encelto, Ai Proteins Enters Research Collaboration and License Agreement with Astellas Pharma
4
Pharmaceutical Executive Daily: FDA Grants Ultomiris Accelerated Approval in the U.S.
5